# Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

> **NCT03298087** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 28 (actual)

## Conditions studied

- Newly Diagnosed Oligometastatic Prostate Cancer

## Interventions

- **PROCEDURE:** radical prostatectomy
- **RADIATION:** stereotactic body radiotherapy
- **DRUG:** Leuprolide
- **DRUG:** apalutamide
- **DRUG:** abiraterone

## Key facts

- **NCT ID:** NCT03298087
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-01
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298087, "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03298087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*